

Oxurion NV – COVID-19 Statement

Leuven, Belgium, 28 March 2020

- Phase 2 study THR-149 in Diabetic Macular Edema (DME): start of study delayed until COVID-19 related safety considerations allow. Preparation work to continue as planned.
- Phase 2 study THR-687 in Diabetic Macular Edema (DME): preparations to start study in Q1 2021. Currently no change.
- Phase 1/2a study TB-403 in medulloblastoma (Oncurious): study recruiting.

Company does not expect COVID-19 to impact current cash management guidance as communicated in its Full YearY19 Business Update (March 12, 2020)

END

For further information please contact:

<p><u>Oxurion NV</u> Wouter Piepers, Global Head of Investor Relations & Corporate Communications Tel: +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@oxurion.com</p>	<p><u>Citigate Dewe Rogerson</u> David Dible/ Sylvie Berrebi/Frazer Hall Tel: +44 20 7638 9571 oxurion@citigatedewerogerson.com</p>
--	---